Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Tarih
2015Yazar
STEINSSON, Kristjan
BAE, Sang-Cheol
SANCHEZ-GUERRERO, Jorge
ROMERO-DIAZ, Juanita
Gordon, Caroline
WALLACE, Daniel J.
Clarke, Ann E.
Bernatsky, Sasha
GINZLER, Ellen M.
Isenberg, David A.
Rahman, Anisur
MERRILL, Joan T.
ALARCON, Graciela S.
FESSLER, Barri J.
Fortin, Paul R.
HANLY, John G.
Petri, Michelle
Dooley, Mary Anne
MANZI, Susan
KHAMASHTA, Munther A.
Ramsey-Goldman, Rosalind
ZOMA, Asad A.
Sturfelt, Gunnar K.
Nived, Ola
ARANOW, Cynthia
MACKAY, Meggan
RAMOS-CASALS, Manuel
van Vollenhoven, Ronald F.
Peschken, Christine A.
Bruce, Ian N.
Inanc, Murat
KALUNIAN, Kenneth C.
RUIZ-IRASTORZA, Guillermo
Lim, S. Sam
KAMEN, Diane L.
Parker, Ben
Urowitz, Murray B.
Gladman, Dafna D.
Lunt, Mark
Donn, Rachelle
Üst veri
Tüm öğe kaydını gösterÖzet
Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.
Koleksiyonlar
- Makale [92796]